Literature DB >> 18783296

Towards quantitative prediction of oral drug absorption.

Jennifer B Dressman1, Kirstin Thelen, Ekarat Jantratid.   

Abstract

Although several routes of administration can be considered for new drug entities, the oral route remains the most popular. To predict the in vivo performance of a drug after oral administration from in vitro data, it is essential that the factors limiting absorption can be modelled. Factors limiting oral drug absorption are typically slow and/or incomplete dissolution, formation of insoluble complexes and/or decomposition in the gastrointestinal lumen, poor net permeability and first-pass metabolism. Although many attempts have been made to make global forecasts of oral bioavailability based on a single parameter (ranging from the partition coefficient [logP] to the polar surface area), it is clear from the diversity of properties that can influence delivery of drugs via the oral route that such an approach can at best lead to a qualitative estimation. To predict in vivo performance in a more quantitative way, it is instead necessary to identify the extent to which each of the aforementioned factors can limit absorption, and then combine the information into a comprehensive model of the absorptive processes. Much progress has been made in the last 10 years on developing methods to pin down the extent to which each of the factors actually limits the absorption of a given compound and, concomitantly, physiological models have been evolved, which show promise in terms of being able to integrate the information generated about each of the individual limiting factors. This article attempts to summarize recent progress on the various fronts as a kind of 'progress report' towards quantitative prediction of oral drug absorption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783296     DOI: 10.2165/00003088-200847100-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  80 in total

1.  Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.

Authors:  Maria Vertzoni; Jennifer Dressman; James Butler; John Hempenstall; Christos Reppas
Journal:  Eur J Pharm Biopharm       Date:  2005-08       Impact factor: 5.571

2.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.

Authors:  Martin Kuentz; Sonja Nick; Neil Parrott; Dieter Röthlisberger
Journal:  Eur J Pharm Sci       Date:  2005-10-10       Impact factor: 4.384

3.  Prediction of oral drug absorption in humans by theoretical passive absorption model.

Authors:  Kouki Obata; Kiyohiko Sugano; Ryoichi Saitoh; Atsuko Higashida; Yoshiaki Nabuchi; Minoru Machida; Yosinori Aso
Journal:  Int J Pharm       Date:  2005-04-11       Impact factor: 5.875

4.  Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.

Authors:  Ekarat Jantratid; Sompol Prakongpan; Gordon L Amidon; Jennifer B Dressman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Felodipine kinetics in healthy men.

Authors:  B Edgar; C G Regårdh; G Johnsson; L Johansson; P Lundborg; I Löfberg; O Rönn
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

6.  Comparison of oral absorption and bioavailablity of drugs between monkey and human.

Authors:  Win L Chiou; Paul W Buehler
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

7.  A physiological model for the estimation of the fraction dose absorbed in humans.

Authors:  Stefan Willmann; Walter Schmitt; Jörg Keldenich; Jörg Lippert; Jennifer B Dressman
Journal:  J Med Chem       Date:  2004-07-29       Impact factor: 7.446

8.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

9.  The human intestinal cytochrome P450 "pie".

Authors:  Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
Journal:  Drug Metab Dispos       Date:  2006-02-07       Impact factor: 3.922

10.  Gentamicin pharmacokinetics during slow daily home hemodialysis.

Authors:  Harold J Manley; George R Bailie; Marcy L McClaran; Walter L Bender
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

View more
  5 in total

1.  Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1.

Authors:  Larryn W Peterson; Monica Sala-Rabanal; Ivan S Krylov; Michaela Serpi; Boris A Kashemirov; Charles E McKenna
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

2.  Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.

Authors:  Long Ye; John M Knapp; Panjamaporn Sangwung; James C Fettinger; A S Verkman; Mark J Kurth
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

3.  The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.

Authors:  Daniel Zakowiecki; Krzysztof Cal; Kamil Kaminski; Karolina Adrjanowicz; Lech Swinder; Ewa Kaminska; Grzegorz Garbacz
Journal:  AAPS PharmSciTech       Date:  2015-01-16       Impact factor: 3.246

Review 4.  Simulation Models for Prediction of Bioavailability of Medicinal Drugs-the Interface Between Experiment and Computation.

Authors:  Mahmoud E Soliman; Adeniyi T Adewumi; Oluwole B Akawa; Temitayo I Subair; Felix O Okunlola; Oluwayimika E Akinsuku; Shahzeb Khan
Journal:  AAPS PharmSciTech       Date:  2022-03-15       Impact factor: 3.246

Review 5.  The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions.

Authors:  K Sandy Pang; H Benson Peng; Keumhan Noh
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.